Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
1–4
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a Type 1 Diabetes diagnosis for at least 6 months
Have been receiving insulin therapy via multiple daily injections or using an insulin pump and have been stable for at least 3 months prior to screening
Have a HbA1c level of ≤ 9.5% at screening
Have sufficient venous access for collection of blood samples
Have good general health, apart from their Type 1 diabetes, with no prior history of choanal atresia, nasal/pharyngeal blockage or nasal anomaly
You may not be if
Have a presence or history of glucagon hypersensitivity
Have a history of pheochromocytoma
Have a history of epilepsy or seizure disorder
Have 1 or more congenital anomalies to the anatomy of the nose, or require changes to the anatomy of the nose
Are using closed-loop insulin therapy, unless such a device is set to 'open loop/manual' mode on the day of the dosing visit
Have an episode of severe hypoglycemia or have had glucagon administered , during the 3 months prior to the screening visit and no severe hypoglycemia between the screening and dosing visit
Clareo Health | A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
